Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Aly

Showing results (31-40 of 84) with videos related to

Pageof 9
Sort By:
BJUI Compass|April 27, 2022
Mortality in men with castration-resistant prostate cancer-A long-term follow-up of a population-based real-world cohortYashar Khoshkar, Marcus Westerberg, Jan Adolfsson, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 19, 2025
Pelvic lymph-node dissections in bladder and prostate cancer surgery and the risk of postoperative venous thromboembolismJuhana Rautiola, Johan Björklund, Renata Zelic, et al.
The New England Journal of Medicine|July 8, 2021
MRI-Targeted or Standard Biopsy in Prostate Cancer ScreeningMartin Eklund, Fredrik Jäderling, Andrea Discacciati, et al.
Scandinavian Journal of Urology|May 13, 2022
Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonistsTiago M Bonde, Marcus Westerberg, Markus Aly, et al.
Scandinavian Journal of Urology|September 2, 2024
A population-based registry cohort study on the correlation between bladder-intact event-free survival and overall survival in cystectomy-ineligible/refusal muscle-invasive bladder cancer patients in SwedenOscar Laurin, Simona Baculea, Sarah Côté, et al.
European Urology Focus|April 9, 2018
Time-to-event Outcomes in Men with Nonmetastatic Castrate-resistant Prostate Cancer-A Systematic Literature Review and Pooling of Individual Participant DataMarkus Aly, Mahmoud Hashim, Bart Heeg, et al.
BMC Urology|August 7, 2019
Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?Kerri Beckmann, Netty Kinsella, Henrik Olsson, et al.
European Urology Focus|July 30, 2017
Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI ProjectTobias Nordström, Wolfgang Picker, Markus Aly, et al.
The Lancet. Oncology|August 15, 2021
Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trialTobias Nordström, Andrea Discacciati, Martin Bergman, et al.
Prostate Cancer and Prostatic Diseases|December 4, 2018
Preoperative staging using magnetic resonance imaging and risk of positive surgical margins after prostate-cancer surgeryFredrik Jäderling, Olof Akre, Markus Aly, et al.
Pageof 9

Showing results (31-40 of 84) with videos related to

Sort By:
Pageof 9
BJUI Compass|April 27, 2022
Mortality in men with castration-resistant prostate cancer-A long-term follow-up of a population-based real-world cohortYashar Khoshkar, Marcus Westerberg, Jan Adolfsson, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 19, 2025
Pelvic lymph-node dissections in bladder and prostate cancer surgery and the risk of postoperative venous thromboembolismJuhana Rautiola, Johan Björklund, Renata Zelic, et al.
The New England Journal of Medicine|July 8, 2021
MRI-Targeted or Standard Biopsy in Prostate Cancer ScreeningMartin Eklund, Fredrik Jäderling, Andrea Discacciati, et al.
Scandinavian Journal of Urology|May 13, 2022
Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonistsTiago M Bonde, Marcus Westerberg, Markus Aly, et al.
Scandinavian Journal of Urology|September 2, 2024
A population-based registry cohort study on the correlation between bladder-intact event-free survival and overall survival in cystectomy-ineligible/refusal muscle-invasive bladder cancer patients in SwedenOscar Laurin, Simona Baculea, Sarah Côté, et al.
European Urology Focus|April 9, 2018
Time-to-event Outcomes in Men with Nonmetastatic Castrate-resistant Prostate Cancer-A Systematic Literature Review and Pooling of Individual Participant DataMarkus Aly, Mahmoud Hashim, Bart Heeg, et al.
BMC Urology|August 7, 2019
Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?Kerri Beckmann, Netty Kinsella, Henrik Olsson, et al.
European Urology Focus|July 30, 2017
Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI ProjectTobias Nordström, Wolfgang Picker, Markus Aly, et al.
The Lancet. Oncology|August 15, 2021
Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trialTobias Nordström, Andrea Discacciati, Martin Bergman, et al.
Prostate Cancer and Prostatic Diseases|December 4, 2018
Preoperative staging using magnetic resonance imaging and risk of positive surgical margins after prostate-cancer surgeryFredrik Jäderling, Olof Akre, Markus Aly, et al.
Pageof 9